<DOC>
	<DOCNO>NCT02919319</DOCNO>
	<brief_summary>The main objective first-into-man study investigate safety , tolerability pharmacokinetic profile single oral dos ACT-541468 healthy male adult . Pharmacodynamic effect ( battery Central Nervous System test ) also assess .</brief_summary>
	<brief_title>A Single Ascending Dose Study ACT-541468 Healthy Male Subjects</brief_title>
	<detailed_description>The study consist ascend dose group ; dose group investigate new group 8 healthy male subject ( 6 active drug 2 placebo ) . In addition , study include biocomparison part ( dose group 2 ) , absolute bioavailability part ( dose group 4 ) , mass balance / metabolism part ( dose group 3 ) .</detailed_description>
	<criteria>Key inclusion Criteria : Signed informed consent prior studymandated procedure . Males age 18 45 year ( inclusive ) screening . Body mass index ( BMI ) 18.0 30.0 kg/m2 ( inclusive ) screening . Systolic blood pressure ( SBP ) , diastolic blood pressure ( DBP ) pulse rate ( PR ) 100145 mmHg , 5090 mmHg 4590 bpm ( inclusive ) screening , respectively . Healthy basis physical examination , electrocardiogram laboratory test . Key exclusion Criteria : Known hypersensitivity excipients drug formulation . History presence disease condition treatment , may put subject risk participation study may interfere absorption , distribution , metabolism excretion study drug . History narcolepsy cataplexy modify Swiss narcolepsy scale total score &lt; 0 screening . Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>